Correction

This article refers to:

Afatinib and Erlotinib in the treatment of squamous-cell lung cancer

Article title: Afatinib and Erlotinib in the treatment of squamous-cell lung cancer

Authors: Tagliamento M, Genova C, Rijavec E, Rossi G, Biello F, Dal Bello MG, Alama A, Coco S, Boccardo S, and Grossi F

Journal: Expert Opinion on Pharmacotherapy

DOI: https://doi.org/10.1080/14656566.2018.1540591

When the above article was first published online, incorrect data was included in Table 1. This has now been corrected as shown below.

Table 1. Relevant efficacy and safety data of LUX-Lung 8.

	Erlotinib	Afatinib	HR	P-value
Outcome analysis
Median PFS (months)	1.9	2.6	0.81	0.0103
Median OS (months)	6.8	7.9	0.81	0.0077
One-year survival rate	28.2%	36.4%		0.0155
DCR	40%	51%		0.0020
Median DOR (months)	3.7	7.3
RR	3% (n = 11)	6% (n = 22)		0.0551
Toxicity profile
Drug-related AE	81% (n = 321)	93% (n = 366)
Grade 3 drug-related AE	16% (n = 64)	25% (n = 99)
Dose reduction due to AE	14% (n = 56)	27% (n = 104)
Discontinuation due to AE	17% (n = 67)	20% (n = 79)

HR: hazard ratio; PFS: progression-free survival; OS: overall survival; DCR: disease control rate; DOR: duration of response; RR: response rate; AE: adverse events.